Lal Karan, Herringshaw Emilee
Dr. Lal is with Affiliated Dermatology in Scottsdale, Arizona, and Northwell Dermatology in Lake Success, New York.
Dr. Herringshaw is with the University of Massachusetts Chan Medical School in Worcester, Massachusetts.
J Clin Aesthet Dermatol. 2024 Sep;17(9):34-37.
Glucagon-like peptide-1 (GLP-1) agonists are a class of medications indicated for type 2 diabetes and obesity that may play a role in the management of cutaneous disease, in part due to their anti-inflammatory effects. These molecules interact with cytokines critical to the development and persistence of skin disease, such as TNF-α, IL-23, IL-17 and IL-22. Correspondingly, immunologic pathways that are downregulated by GLP-1 agonists may serve as a target for various skin conditions that are worsened by inflammation. Furthermore, the known benefit of weight loss for certain skin conditions may be further potentiated by GLP-1 agonists. In this brief report, the authors describe multiple cases of patients with psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease for which patients experienced improvement subsequent to treatment with GLP-1 therapy. These cases demonstrate the utility of GLP-1 agonists in treating dermatologic conditions that are refractory to other therapies and further highlight the potential of GLP-1 agonists in treating skin disease.
胰高血糖素样肽-1（GLP-1）激动剂是一类用于治疗2型糖尿病和肥胖症的药物，可能在皮肤病管理中发挥作用，部分原因是其具有抗炎作用。这些分子与对皮肤病的发生和持续发展至关重要的细胞因子相互作用，如肿瘤坏死因子-α、白细胞介素-23、白细胞介素-17和白细胞介素-22。相应地，被GLP-1激动剂下调的免疫途径可能成为因炎症而恶化的各种皮肤病的治疗靶点。此外，GLP-1激动剂可能会进一步增强已知的减肥对某些皮肤病的益处。在本简要报告中，作者描述了多例银屑病、化脓性汗腺炎、黑棘皮病和黑利-黑利病患者，这些患者在接受GLP-1治疗后病情有所改善。这些病例证明了GLP-1激动剂在治疗对其他疗法难治的皮肤病方面的效用，并进一步突出了GLP-1激动剂在治疗皮肤病方面的潜力。
